Thomas Gad's Insider Trades & SAST Disclosures
Thomas Gad's most recent trade in Y-Mabs Therapeutics Inc was a trade of 10,810 Common Stock done at an average price of $5.2 . Disclosure was reported to the exchange on March 7, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Thomas Gad.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 5.23 per share. | 07 Mar 2025 | 10,810 | 202,721 (0%) | 0% | 5.2 | 56,536 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 64,000 | 64,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 32,000 | 213,531 (0%) | 0% | 0 | Common Stock | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.38 per share. | 19 Sep 2024 | 22,831 | 181,531 (0%) | 0% | 4.4 | 100,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2024 | 22,831 | 143,169 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 13.47 per share. | 13 Sep 2024 | 65,000 | 97,681 (0%) | 0% | 13.5 | 875,550 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 12.97 per share. | 13 Sep 2024 | 30,000 | 67,681 (0%) | 0% | 13.0 | 389,100 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 10 Jun 2024 | 35,000 | 162,681 (0%) | 0% | 12 | 420,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 12.03 per share. | 10 Jun 2024 | 35,000 | 197,681 (0%) | 0% | 12.0 | 421,050 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 21 May 2024 | 25,000 | 240,032 (0%) | 0% | 12 | 300,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 21 May 2024 | 7,351 | 232,681 (0%) | 0% | 13 | 95,563 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 16.44 per share. | 05 Mar 2024 | 3,900 | 158,700 (0%) | 0% | 16.4 | 64,116 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 132,500 | 132,500 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 22,100 | 162,600 (0%) | 0% | 0 | Common Stock | |
| Y-Mabs Therapeutics Inc | Gad Thomas | Director, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2023 | 50,000 | 103,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Gad Thomas | Director, Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 21 Dec 2023 | 50,000 | 140,500 (0%) | 0% | 2 | 100,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Gad Thomas | Director, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 6.61 per share. | 13 Dec 2023 | 50,000 | 265,032 (0%) | 0% | 6.6 | 330,500 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 6.83 per share. | 13 Dec 2023 | 50,000 | 315,032 (0%) | 0% | 6.8 | 341,500 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, Chief Business Officer | Sale of securities on an exchange or to another person at price $ 6.58 per share. | 13 Dec 2023 | 50,000 | 365,032 (0%) | 0% | 6.6 | 329,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 243,200 | 243,200 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 40,500 | 90,500 (0%) | 0% | 0 | Common Stock | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 7.01 per share. | 07 Feb 2022 | 125,863 | 629,308 (1%) | 0% | 7.0 | 882,891 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 7.59 per share. | 07 Feb 2022 | 91,031 | 755,171 (1%) | 0% | 7.6 | 691,180 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 6.96 per share. | 07 Feb 2022 | 64,276 | 565,032 (1%) | 0% | 7.0 | 447,117 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 7.70 per share. | 03 Feb 2022 | 101,104 | 846,202 (2%) | 0% | 7.7 | 778,531 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 7.90 per share. | 03 Feb 2022 | 35,060 | 947,306 (2%) | 0% | 7.9 | 277,027 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 01 Feb 2022 | 8,000 | 58,000 (0%) | 0% | 2 | 16,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 10.15 per share. | 01 Feb 2022 | 8,000 | 50,000 (0%) | 0% | 10.1 | 81,161 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 8,000 | 153,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 10.96 per share. | 24 Jan 2022 | 55,783 | 982,366 (2%) | 0% | 11.0 | 611,281 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 10.07 per share. | 24 Jan 2022 | 32,272 | 1,038,149 (2%) | 0% | 10.1 | 325,131 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 11.33 per share. | 20 Jan 2022 | 112,767 | 1,140,739 (2%) | 0% | 11.3 | 1,277,289 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 10.51 per share. | 20 Jan 2022 | 50,134 | 1,090,605 (2%) | 0% | 10.5 | 526,713 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 11.35 per share. | 20 Jan 2022 | 20,184 | 1,070,421 (2%) | 0% | 11.4 | 229,103 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 10.89 per share. | 18 Jan 2022 | 69,414 | 1,253,506 (3%) | 0% | 10.9 | 756,092 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 18 Jan 2022 | 8,000 | 58,000 (0%) | 0% | 2 | 16,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 8,000 | 161,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 11.54 per share. | 18 Jan 2022 | 8,000 | 50,000 (0%) | 0% | 11.5 | 92,314 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 11.46 per share. | 18 Jan 2022 | 400 | 1,322,920 (3%) | 0% | 11.5 | 4,584 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 110,000 | 110,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Dec 2021 | 60,000 | 1,383,320 (3%) | 0% | 0 | Common Stock | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Dec 2021 | 60,000 | 1,323,320 (3%) | 0% | 0 | Common Stock | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 16.48 per share. | 06 Dec 2021 | 40,000 | 1,397,320 (3%) | 0% | 16.5 | 659,260 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 17.58 per share. | 06 Dec 2021 | 10,000 | 1,383,320 (3%) | 0% | 17.6 | 175,832 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 16.50 per share. | 06 Dec 2021 | 4,000 | 1,393,320 (3%) | 0% | 16.5 | 65,982 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 17.16 per share. | 29 Nov 2021 | 22,437 | 1,462,490 (3%) | 0% | 17.2 | 385,026 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 17.11 per share. | 29 Nov 2021 | 12,800 | 1,449,090 (3%) | 0% | 17.1 | 218,947 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 17.04 per share. | 29 Nov 2021 | 7,770 | 1,441,320 (3%) | 0% | 17.0 | 132,433 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 16.98 per share. | 29 Nov 2021 | 4,000 | 1,437,320 (3%) | 0% | 17.0 | 67,912 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 16.94 per share. | 29 Nov 2021 | 600 | 1,461,890 (3%) | 0% | 16.9 | 10,166 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 23 Nov 2021 | 50,000 | 100,000 (0%) | 0% | 2 | 100,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2021 | 50,000 | 169,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 17.06 per share. | 23 Nov 2021 | 50,000 | 50,000 (0%) | 0% | 17.1 | 852,850 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 19.33 per share. | 16 Nov 2021 | 4,000 | 1,484,927 (3%) | 0% | 19.3 | 77,302 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 24.82 per share. | 29 Oct 2021 | 4,000 | 1,488,927 (3%) | 0% | 24.8 | 99,261 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 27.20 per share. | 15 Oct 2021 | 4,000 | 1,492,927 (3%) | 0% | 27.2 | 108,799 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 28.26 per share. | 30 Sep 2021 | 4,000 | 1,496,927 (3%) | 0% | 28.3 | 113,054 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 33.64 per share. | 15 Sep 2021 | 4,000 | 1,500,927 (3%) | 0% | 33.6 | 134,579 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 33.18 per share. | 02 Sep 2021 | 50,000 | 1,504,927 (3%) | 0% | 33.2 | 1,658,915 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2021 | 50,000 | 219,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 02 Sep 2021 | 50,000 | 50,000 (0%) | 0% | 2 | 100,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 29.33 per share. | 13 Aug 2021 | 22,111 | 1,556,706 (3%) | 0% | 29.3 | 648,527 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 29.14 per share. | 13 Aug 2021 | 4,000 | 1,578,817 (3%) | 0% | 29.1 | 116,544 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 28.96 per share. | 13 Aug 2021 | 1,779 | 1,554,927 (3%) | 0% | 29.0 | 51,527 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 31.01 per share. | 13 Aug 2021 | 1,110 | 1,582,817 (3%) | 0% | 31.0 | 34,426 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 33.73 per share. | 03 Aug 2021 | 4,000 | 1,583,927 (3%) | 0% | 33.7 | 134,927 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 32.47 per share. | 20 Jul 2021 | 4,000 | 1,587,927 (3%) | 0% | 32.5 | 129,875 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 31.87 per share. | 07 Jul 2021 | 4,000 | 1,591,927 (4%) | 0% | 31.9 | 127,465 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 33.86 per share. | 30 Jun 2021 | 4,000 | 1,595,927 (4%) | 0% | 33.9 | 135,446 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 36.95 per share. | 28 May 2021 | 4,000 | 1,603,927 (4%) | 0% | 37.0 | 147,813 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 34.07 per share. | 18 May 2021 | 4,000 | 1,607,927 (4%) | 0% | 34.1 | 136,290 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 27.96 per share. | 26 Apr 2021 | 7,000 | 0 (0%) | 0% | 28.0 | 195,731 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2021 | 7,000 | 269,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 26 Apr 2021 | 7,000 | 7,000 (0%) | 0% | 2 | 14,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 26.61 per share. | 12 Apr 2021 | 7,000 | 0 (0%) | 0% | 26.6 | 186,253 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2021 | 7,000 | 276,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 12 Apr 2021 | 7,000 | 7,000 (0%) | 0% | 2 | 14,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 26.60 per share. | 12 Apr 2021 | 4,000 | 1,611,927 (4%) | 0% | 26.6 | 106,388 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 30.26 per share. | 01 Apr 2021 | 9,000 | 0 (0%) | 0% | 30.3 | 272,331 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 9,000 | 283,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 01 Apr 2021 | 9,000 | 9,000 (0%) | 0% | 2 | 18,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 30.27 per share. | 01 Apr 2021 | 6,000 | 1,615,927 (4%) | 0% | 30.3 | 181,615 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 15 Mar 2021 | 7,000 | 7,000 (0%) | 0% | 2 | 14,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 7,000 | 292,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 15 Mar 2021 | 7,000 | 0 (0%) | 0% | 36.8 | 257,554 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 36.78 per share. | 15 Mar 2021 | 4,000 | 1,621,927 (4%) | 0% | 36.8 | 147,102 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Other type of transaction at price $ 0.00 per share. | 10 Mar 2021 | 1,029,927 | 1,625,927 (4%) | 2% | - | Common Stock | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 35.51 per share. | 01 Mar 2021 | 9,000 | 0 (0%) | 0% | 35.5 | 319,611 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 9,000 | 299,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 01 Mar 2021 | 9,000 | 9,000 (0%) | 0% | 2 | 18,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 35.50 per share. | 01 Mar 2021 | 6,000 | 596,000 (1%) | 0% | 35.5 | 213,029 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 47.08 per share. | 16 Feb 2021 | 7,000 | 0 (0%) | 0% | 47.1 | 329,556 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 7,000 | 308,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 16 Feb 2021 | 7,000 | 7,000 (0%) | 0% | 2 | 14,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 47.09 per share. | 16 Feb 2021 | 4,000 | 602,000 (1%) | 0% | 47.1 | 188,367 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 41.99 per share. | 01 Feb 2021 | 7,000 | 0 (0%) | 0% | 42.0 | 293,897 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 7,000 | 315,000 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 01 Feb 2021 | 7,000 | 7,000 (0%) | 0% | 2 | 14,000 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 41.97 per share. | 01 Feb 2021 | 4,000 | 606,000 (1%) | 0% | 42.0 | 167,888 | Common Stock |
| Y-Mabs Therapeutics Inc | Thomas Gad | Director, See remarks | Sale of securities on an exchange or to another person at price $ 46.51 per share. | 19 Jan 2021 | 7,000 | 0 (0%) | 0% | 46.5 | 325,563 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges